JNJ-6143

1. 01:37
   ESMO 2026 现场信号

   Benjamin Garmezy, MD, on JNJ-6143, a first-in-class oral AR-targeted RIPTAC™, at the optimal dose in metastatic prostate cancer, including high-risk molecular features. #ESMO26

1. 03:54
   ESMO 2026 现场信号

   Halda’s prostate promise holds up for $JNJ at #ESMO26. My take on the latest results with the Riptac JNJ-6143 https://www.apexonco.com/esmo-2026-haldas-prostate-promise-holds-jj
2. 03:30
   ESMO 2026 现场信号

   JNJ-6143, a First-in-Class Oral AR-Targeted RIPTAC, in Heavily Pretreated #mCRPC: Phase 1 Safety and Efficacy. Presented by @BGarmezy @SarahCannonDocs. #ESMO26 written coverage by

1. 21:08
   ESMO 2026 现场信号

   Safety/efficacy of JNJ-6143, a first-in-class RIPTAC in heavily pre-Rxed pts with mCRPC @BGarmezy @urotoday #ESMO26
2. 17:02
   ESMO 2026 现场信号

   Promising #ESMO2026 data for JNJ-6143, a first-in-class oral RIPTAC in heavily pretreated #mCRPC.
3. 16:59
   ESMO 2026 现场信号

   🚨 #ESMO26 | JNJ-6143: A new therapeutic paradigm in mCRPC? RIPTAC
4. 16:54
   ESMO 2026 现场信号

   JNJ-6143: A first-in-class RIPTAC with a novel mechanism of action targeting AR and BRD4.
5. 16:54
   ESMO 2026 现场信号

   @BGarmezy with 1st report of an AR RIPTAC - JNJ-6143 in metastatic castration resistant #prostatecancer showing good PSA responses across aggressive molecular subtypes, median dura
6. 16:51
   ESMO 2026 现场信号

   Thrilled for @BGarmezy to present updated results for JNJ-6143. @JNJInnovMed team are excited about these results and the potential to provide patients with more tomorrows and bett
7. 16:51
   ESMO 2026 现场信号

   1/5
8. 16:47
   ESMO 2026 现场信号

   @BGarmezy presenting incredible Ph I data in mCRPC with JNJ-6143 (RIPTAC): 75% ORR (incl CRs - heavily pretreated). Ph 2 underway. #ESMO26 @SarahCannonDocs
9. 16:37
   ESMO 2026 现场信号

   JNJ-6143 phase I study (RIPTAC): good safety profile, with high response rates in a heavily pretreated population with mCRPC. A new mechanism of action has arrived. #ESMO26
10. 16:35
    ESMO 2026 现场信号

    Exciting early data at #ESMO26 for JNJ-6143, a first-in-class oral AR-targeted RIPTAC in heavily pretreated #mCRPC @BGarmezy @OncoAlert
11. 15:35
    ESMO 2026 现场信号

    Stay tuned for the presentation of JNJ-6143, a riptac molecule, in patients with mCRPC. Barcelona Auditorium. Hall 9 at #ESMO2026. @SarahCannonDocs @SCRIOncology. Particular thanks

1. 22:34
   ESMO 2026 现场信号

   🚨⭐🔵 #ESMO26 Novel AR targeted therapies in mCRPC

当前热度 20·可比范围峰值 105（10月25日 04:00）·近 24 小时可比范围变化 -32%·当前参与者 15

上图是参与者计数，下图是热度。趋势仅比较持续完整观测到的相同主体，范围可能小于当前热度统计。移动指针或点击图表查看每小时读数；键盘可用左右方向键切换。